Update: The coming into force date of the amended Patented Medicines Regulations governing the Patented Medicine Prices Review Board (PMPRB) has been deferred, once again, until July 1, 2022, which as announced on April 14, 2022, will be released in a substantially amended form.
Further to our June 1, 2020 update, regulations amending the coming into force date of the Regulations Amending the Patented Medicines Regulations (Additional Factors and Information Reporting Requirements) (the “Amended Regulations”) were published this morning in Part II of the Canada Gazette.
These new regulations—officially titled Regulations Amending the Regulations Amending the Patented Medicines Regulations (Additional Factors and Information Reporting Requirements)—were registered on June 1, 2020 and came into force on that date.
The newly registered regulations generally push back the timelines in the Amended Regulations by six months. As previously announced, the coming into force date of the Amended Regulations has been moved from July 1, 2020, to January 1, 2021. Similarly, section 4.4 of the Amended Regulations previously required the Board to consider excessive pricing based on the three new pharmacoeconomic factors for sales in Canada after June 30, 2020. Under the new amendments, the PMPRB will conduct that assessment for sales after December 31, 2020. Analogous revisions were made to subsection 4.2(4), which sets deadlines for providing the estimated maximum use of a medicine, and subsection 4.1(4), which governs the provision of cost-utility analyses.
We have prepared an unofficial consolidated version of the Patented Medicines Regulations incorporating the amendments.
The preceding is intended as a timely update on Canadian intellectual property and technology law. The content is informational only and does not constitute legal or professional advice. To obtain such advice, please communicate with our offices directly.
Related Publications & Articles
-
FCA finds Teva would directly infringe and induce infringement of Janssen’s paliperidone palmitate patent
As previously reported, the Federal Court found that Teva would directly infringe but not induce infringement of certain claims of Canadian Patent No. 2,655,335 (335 patent) regarding its paliperidone...Read More -
House of Commons Standing Committee on Health meets for study of the PMPRB
The Standing Committee on Health (HESA) of the House of Commons met on Thursday, April 27, 2023, to begin its study of the Patented Medicine Prices Review Board (PMPRB).Read More -
Proposed legislation for patent term adjustment, and the interplay with CSPs
Bill C-47 is an omnibus bill that includes proposed amendments to the Patent Act to introduce patent term adjustment to compensate the patentee for Patent Office delays in granting a patent.Read More